GlassScriptPhysician profile
Ali Ayyash
NPI 1467913186
$4,372.53
in general payments reported to CMS, 2019-2025
16 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $1,417 · 2023: $318 · 2024: $698 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.63 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,005.66 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Csl Behring | $448.95 | 2022-2025 | Hizentra, Andembry, Haegarda |
| Astrazeneca Pharmaceuticals LP | $440.67 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $233.09 | 2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $230.07 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $220.87 | 2025 | Xolair |
| Horizon Therapeutics Plc | $149.86 | 2022 | |
| Grifols USA, LLC | $142.12 | 2024-2025 | Xembify |
| Amgen INC. | $141.93 | 2024-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.13 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $65.13 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $57.13 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.68 | 2025 | Hyqvia, Eohilia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $22.76 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Ayyash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.